查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571764

肺癌診斷市場規模、佔有率、趨勢分析報告：按類型、測試、最終用途、地區、細分市場預測，2024-2030 年

Lung Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test (CA Tests, HER2 Tests, ALK Tests), By End Use, Region And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

肺癌診斷市場的成長與趨勢：

Grand View Research Inc.最新報告顯示，預計2030年全球肺癌診斷市場規模將達72.6億美元，2024年至2030年複合年成長率為6.5%。

肺癌特異性生物標記的開拓是預測期內肺癌診斷市場成長的關鍵驅動力之一。這些診斷工具促進了肺部惡性的個人化治療方法。

研究管道中存在多種生物標記。例如，2015 年 11 月，Epigenomics AG 宣布推出一種使用 DNA 甲基化生物標記的新型血液測試，該測試的開發正在進行中。該測試的初步結果顯示了肺癌早期診斷的有希望的結果。

此外，還啟動了各種針對肺癌及相關症狀的宣傳計劃，以提高惡性高風險族群的篩檢和診斷率。例如，11 月是英國的肺癌宣傳月，由羅伊城堡肺癌基金會支持。

肺癌診斷市場報告亮點

  • 2023年，非小細胞肺癌（NSCLC）領域將佔據主導地位，並佔據可觀的收益佔有率。 NSCLC又分為肺鱗狀細胞癌、腺癌和大細胞癌。
  • EGFR突變檢測在2023年佔據市場主導地位，市場佔有率為29.2%。表皮生長因子受體（EGFR）是 NSCLC 患者中最常見的激動性突變之一。
  • 醫院和診所細分市場在 2023 年佔據主導地位。這是因為我們的設施擁有先進的診斷工具和影像技術，可以準確檢測和分期肺癌。
  • 由於先進的醫療基礎設施、高昂的醫療成本以及嚴格的癌症診斷報銷規定，北美在 2023 年將主導全球肺癌診斷市場。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章肺癌診斷市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 肺癌診斷市場分析工具
    • 波特的分析
    • PESTEL分析

第4章肺癌診斷市場：按類型估計和趨勢分析

  • 細分儀表板
  • 肺癌診斷市場：2023 年和 2030 年按類型分類的變異分析
  • 非小細胞肺癌
  • 小細胞肺癌

第5章肺癌診斷市場：透過測試進行的估計和趨勢分析

  • 細分儀表板
  • 肺癌診斷市場：2023 年和 2030 年測試變異分析
  • CA測試
  • HER2測試
  • ALK測試
  • 血管新生抑制劑
  • EGFR突變檢測
  • KRAS突變測試

第6章肺癌診斷市場：依最終用途分類的估計與趨勢分析

  • 細分儀表板
  • 肺癌診斷市場：2023 年和 2030 年最終用途的變異分析
  • 醫院和診所
  • 診斷實驗室
  • 其他

第7章肺癌診斷市場：按地區估算及趨勢分析

  • 2023 年及 2030 年肺癌診斷市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific
    • Illumina Inc.
    • Agilent Technologies
    • Qiagen
    • Abbott
    • Bio-Rad
    • Neogenomics Laboratories
    • bioMerieux
    • Myriad Genetics, Inc
簡介目錄
Product Code: 978-1-68038-888-6

Lung Cancer Diagnostics Market Growth & Trends:

The global lung cancer diagnostics market is expected to reach USD 7.26 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies.

Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer.

Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation.

Lung Cancer Diagnostics Market Report Highlights:

  • The non-small cell lung cancer (NSCLC) segment dominated with a substantial revenue share in 2023. NSCLC is further trifurcated into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.
  • EGFR mutation tests dominated the market with a 29.2% market share for 2023. Epidermal Growth Factor Receptor (EGFR) is one of the most prevalent actionable mutations in patients with NSCLC.
  • The hospitals and clinics segment dominated the market in 2023. This is attributed to the facilities with superior diagnostic tools and imaging technologies accounting for accurate lung cancer detection and staging.
  • North America dominated the global lung cancer diagnostics market in 2023 due to its advanced healthcare infrastructure, high healthcare spending, and strong reimbursement regulations for cancer diagnostics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Lung Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Lung Cancer Diagnostics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. Lung Cancer Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Lung Cancer Diagnostics Market: Type Movement Analysis, USD Billion, 2023 & 2030
  • 4.3. Non-small Cell Lung Cancer
    • 4.3.1. Non-small Cell Lung Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Small Cell Lung Cancer
    • 4.4.1. Small Cell Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Lung Cancer Diagnostics Market: Test Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Lung Cancer Diagnostics Market: Test Movement Analysis, USD Million, 2023 & 2030
  • 5.3. CA Tests
    • 5.3.1. CA Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. HER2 Tests
    • 5.4.1. HER2 Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. ALK Tests
    • 5.5.1. ALK Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Angiogenesis Inhibitors
    • 5.6.1. Angiogenesis Inhibitors Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. EGFR Mutation Tests
    • 5.7.1. EGFR Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. KRAS Mutation Tests
    • 5.8.1. KRAS Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Lung Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Lung Cancer Diagnostic Market: End Use Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals and clinics
    • 6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Diagnostic Laboratories
    • 6.4.1. Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Lung Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Lung Cancer Diagnostics Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Thermo Fisher Scientific
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Illumina Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Agilent Technologies
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Qiagen
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Abbott
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bio-Rad
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Neogenomics Laboratories
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. bioMerieux
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Myriad Genetics, Inc
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives